MXPA05011523A - Heteroarilos sustituidos como inhibidores de proteinas de tirosina fosfatasas. - Google Patents

Heteroarilos sustituidos como inhibidores de proteinas de tirosina fosfatasas.

Info

Publication number
MXPA05011523A
MXPA05011523A MXPA05011523A MXPA05011523A MXPA05011523A MX PA05011523 A MXPA05011523 A MX PA05011523A MX PA05011523 A MXPA05011523 A MX PA05011523A MX PA05011523 A MXPA05011523 A MX PA05011523A MX PA05011523 A MXPA05011523 A MX PA05011523A
Authority
MX
Mexico
Prior art keywords
protein tyrosine
compounds
inhibitors
tyrosine phosphatases
substituted heteroaryls
Prior art date
Application number
MXPA05011523A
Other languages
English (en)
Inventor
Garrett Parker
Original Assignee
Inst For Pharm Discovery Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst For Pharm Discovery Inc filed Critical Inst For Pharm Discovery Inc
Publication of MXPA05011523A publication Critical patent/MXPA05011523A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/84—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Abstract

(Ver Formula I) Se describen compuestos y sales farmaceuticamente aceptables de la formula (I) que son utiles en el tratamiento de trastornos metabolicos relacionados con la resistencia a la insulina, resistencia a la leptina o hiperglicemia. Los compuestos de la invencion incluyen inhibidores de las proteinas de tirosina fosfatasas, en particular las proteinas de tirosina fosfatasas 1B (PTP-1B) que son utiles en el tratamiento de la diabetes y de otras enfermedades mediadas por PTP, tales como el cancer, enfermedades neurodegenerativas y similares. Tambien se describen composiciones farmaceuticas que comprenden los compuestos de la invencion y metodos de tratamiento de las condiciones antes mencionadas usando tales compuestos.
MXPA05011523A 2003-04-30 2004-04-30 Heteroarilos sustituidos como inhibidores de proteinas de tirosina fosfatasas. MXPA05011523A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46686903P 2003-04-30 2003-04-30
PCT/US2004/013579 WO2004099159A1 (en) 2003-04-30 2004-04-30 Substituted heteroaryls as inhibitors of protein tyrosine phosphatases

Publications (1)

Publication Number Publication Date
MXPA05011523A true MXPA05011523A (es) 2006-01-23

Family

ID=33434990

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05011523A MXPA05011523A (es) 2003-04-30 2004-04-30 Heteroarilos sustituidos como inhibidores de proteinas de tirosina fosfatasas.

Country Status (11)

Country Link
US (1) US20050009817A1 (es)
EP (1) EP1618094B1 (es)
JP (1) JP2006525357A (es)
AT (1) ATE372324T1 (es)
AU (1) AU2004236239A1 (es)
CA (1) CA2524221A1 (es)
DE (1) DE602004008762T2 (es)
ES (1) ES2290743T3 (es)
MX (1) MXPA05011523A (es)
WO (1) WO2004099159A1 (es)
ZA (1) ZA200509632B (es)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
ES2445208T3 (es) 2002-07-29 2014-02-28 Rigel Pharmaceuticals, Inc. Compuestos de 2,4-pirimidindiamina para uso en métodos para tratar o prevenir enfermedades autoinmunitarias
KR101201603B1 (ko) 2003-07-30 2012-11-14 리겔 파마슈티칼스, 인크. 자가면역 질환의 치료 또는 예방에 사용하기 위한2,4-피리미딘디아민 화합물
AU2004289303A1 (en) * 2003-11-10 2005-05-26 Synta Pharmaceuticals, Corp. Fused heterocyclic compounds
KR100915481B1 (ko) * 2004-11-09 2009-09-03 에프. 호프만-라 로슈 아게 아미노퀴나졸린 화합물
JP2008520692A (ja) * 2004-11-18 2008-06-19 ジ インスチチュート フォー ファーマシューティカル ディスカバリー、エルエルシー 複素環置換カルボン酸
ATE451381T1 (de) 2005-01-19 2009-12-15 Rigel Pharmaceuticals Inc Prodrugs aus 2,4-pyrimidindiamin-verbindungen und ihre verwendungen
CN101142198B (zh) 2005-02-17 2012-10-31 辛塔制药公司 用于治疗疾病的异*唑坎布雷它斯丁衍生物
JP2008536867A (ja) * 2005-04-14 2008-09-11 ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド 増殖疾患を処置する際に有用なｈｓｐ９０インヒビターとしての２−アミノ−キナゾリン−５−オン
US20070203161A1 (en) 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
US7491732B2 (en) 2005-06-08 2009-02-17 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the JAK pathway
US8686002B2 (en) 2005-08-21 2014-04-01 AbbVie Deutschland GmbH & Co. KG Heterocyclic compounds and their use as binding partners for 5-HT5 receptors
AU2006283211B2 (en) * 2005-08-22 2012-06-21 Melior Pharmaceuticals I, Inc. Methods and formulations for modulating Lyn kinase activity and treating related disorders
US8962643B2 (en) 2006-02-24 2015-02-24 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the JAK pathway
TW200813018A (en) 2006-06-09 2008-03-16 Astrazeneca Ab Novel compounds
RU2009106722A (ru) * 2006-07-28 2010-09-10 Новартис АГ (CH) 2,4-замещенные хиназолины в качестве ингибиторов липидной киназы
ES2648388T3 (es) 2006-08-23 2018-01-02 Kudos Pharmaceuticals Limited Derivados de 2-metilmorfolin pirido-, pirazo- y pirimido-pirimidina como inhibidores de mTOR
WO2008072850A1 (en) * 2006-12-11 2008-06-19 Amorepacific Corporation Triazine derivatives having inhibitory activity against acetyl-coa carboxylase
US20100152215A1 (en) * 2007-02-20 2010-06-17 Melior Pharmaceuticals I, Inc. Methods of identifying activators of lyn kinase
KR20090130051A (ko) 2007-03-14 2009-12-17 엑셀리시스, 인코포레이티드 헤지호그 경로의 억제제
JP2010534668A (ja) * 2007-07-23 2010-11-11 メリオール・ディスカヴァリー・インコーポレイテッド Ｉｒｓ−１及びａｋｔを活性化する方法
US8119661B2 (en) 2007-09-11 2012-02-21 Astrazeneca Ab Piperidine derivatives and their use as muscarinic receptor modulators
CN101531638B (zh) * 2008-03-13 2011-12-28 中国科学院广州生物医药与健康研究院 用作***相关受体调节剂的化合物及其应用
JP5607614B2 (ja) 2008-06-20 2014-10-15 アストラゼネカ アクチボラグ 組成物及び方法−３５６
US8552184B2 (en) * 2008-07-03 2013-10-08 Melior Pharmaceuticals I, Inc. Compounds and methods for treating disorders related to glucose metabolism
EA019970B8 (ru) 2009-12-11 2014-11-28 Отифони Терапеутикс Лимитед Производные имидазолидиндиона
TWI453202B (zh) * 2010-03-23 2014-09-21 Scinopharm Taiwan Ltd 製備拉帕替尼之方法及中間體
ES2622519T3 (es) 2010-07-14 2017-07-06 Novartis Ag Componentes heterocíclicos agonistas del receptor IP
BR112013013914B1 (pt) 2010-12-06 2021-10-26 Autifony Therapeutics Limited Compostos derivados de hidantoína úteis como inibidores de kv3, usos dos referidos compostos e composição farmacêutica compreendendo os mesmos
WO2012168710A1 (en) 2011-06-07 2012-12-13 Autifony Therapeutics Limited Hydantoin derivates as kv3 inhibitors
WO2013043255A1 (en) * 2011-09-21 2013-03-28 University Of South Alabama Methods and compositions for the treatment of ovarian cancer
ES2565826T3 (es) 2012-01-13 2016-04-07 Novartis Ag Pirroles fusionados como agonistas del receptor IP para el tratamiento de hipertensión arterial pulmonar (PAH) y trastornos relacionados
BR112014028718A2 (pt) 2012-05-22 2017-06-27 Autifony Therapeutics Ltd derivados de hidantoína como inibidores de kv3
EP2852589B1 (en) 2012-05-22 2021-04-28 Autifony Therapeutics Limited Triazoles as kv3 inhibitors
JO3407B1 (ar) 2012-05-31 2019-10-20 Eisai R&D Man Co Ltd مركبات رباعي هيدرو بيرازولو بيريميدين
CN104768946B (zh) 2012-07-20 2017-05-03 克里弗生物科学公司 作为p97复合物的抑制剂的稠合嘧啶
US9604981B2 (en) 2013-02-13 2017-03-28 Novartis Ag IP receptor agonist heterocyclic compounds
KR101658111B1 (ko) 2013-05-13 2016-09-20 제일모직 주식회사 유기광전자소자용 화합물, 이를 포함하는 유기발광소자 및 상기 유기발광소자를 포함하는 표시장치
AR099134A1 (es) 2014-01-24 2016-06-29 Hoffmann La Roche Procedimiento para la preparación de n-[(3-aminooxetán-3-il)metil]-2-(1,1-dioxo-3,5-dihidro-1,4-benzotiazepín-4-il)-6-metil-quinazolín-4-amina
CN105153048B (zh) * 2015-07-31 2017-10-24 苏州大学 一种2,4‑喹唑啉二酮类化合物的制备方法
CA3001799A1 (en) 2015-10-21 2017-04-27 Otsuka Pharmaceutical Co., Ltd. Benzolactam compounds as protein kinase inhibitors
JP7182605B2 (ja) 2017-04-10 2022-12-02 メリオール・ファーマスーティカルズ・ワン・インコーポレイテッド ｌｙｎキナーゼ活性化因子及びＴＲＰＭ８アゴニストを含む組成物及び医薬の製造におけるそれらの使用
GB201706327D0 (en) 2017-04-20 2017-06-07 Otsuka Pharma Co Ltd A pharmaceutical compound
CN113416181B (zh) * 2021-08-02 2022-05-03 四川大学 喹唑啉类衍生物及其用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3515724A (en) * 1966-12-12 1970-06-02 Hoffmann La Roche Process for the preparation of substituted 4-phenyl or 4-pyridyl-1,2-dihydro-quinazoline compounds and novel substituted 4 - pyridyl-1,2-dihydroquinazoline products
BE790679A (fr) * 1971-11-03 1973-04-27 Ici Ltd Derives de l'indole
US4012513A (en) * 1971-11-03 1977-03-15 Imperial Chemical Industries Limited Indole derivatives for providing analgesic and anti-inflammatory effects
GB2002746A (en) * 1977-06-17 1979-02-28 Gist Brocades Nv Copper complexes
FR2514765A1 (fr) * 1981-10-21 1983-04-22 Sanofi Sa Nouveaux derives de la phenyl-4 quinazoline actifs sur le systeme nerveux central
FR2521144A1 (fr) * 1982-02-08 1983-08-12 Sanofi Sa Nouveaux derives de la piperazinyl-2 phenyl-4 quinazoline possedant des proprietes antidepressives, methode de preparation desdits composes et medicaments en contenant
EP0664128A4 (en) * 1992-10-07 1997-12-17 Sumitomo Pharma PHARMACEUTICAL AGENT FOR INHIBITING TUMORNESCROSE FACTOR PRODUCTION.
NO306992B1 (no) * 1993-01-28 2000-01-24 Takeda Chemical Industries Ltd Quinolinderivater, farmasoeytiske preparater inneholdende forbindelsene og anvendelsen av forbindelsene
JPH11209350A (ja) * 1998-01-26 1999-08-03 Eisai Co Ltd 含窒素複素環誘導体およびその医薬
DE60028791T2 (de) * 1999-09-10 2007-05-24 Novo Nordisk A/S Modulatoren der protein tyrosin phosphatase (ptpases)

Also Published As

Publication number Publication date
AU2004236239A1 (en) 2004-11-18
ATE372324T1 (de) 2007-09-15
CA2524221A1 (en) 2004-11-18
WO2004099159A1 (en) 2004-11-18
DE602004008762D1 (de) 2007-10-18
ZA200509632B (en) 2007-02-28
DE602004008762T2 (de) 2008-06-12
EP1618094B1 (en) 2007-09-05
JP2006525357A (ja) 2006-11-09
US20050009817A1 (en) 2005-01-13
ES2290743T3 (es) 2008-02-16
EP1618094A1 (en) 2006-01-25

Similar Documents

Publication Publication Date Title
MXPA05011523A (es) Heteroarilos sustituidos como inhibidores de proteinas de tirosina fosfatasas.
MXPA05011539A (es) Acidos carboxilicos sustituidos con heterociclo como inhibidores de la proteina tirosina-fosfatasa-1b.
MXPA05011536A (es) Acidos carboxilicos substituidos con fenilo como inhibidores de la proteina tirosina fosfatasa-1b.
MXPA05011537A (es) Acidos aminocaboxilicos sustituidos.
TW200630354A (en) Substituted amino carboxylic acids
WO2006055625A3 (en) Heterocyclylbiphenyl derivates as protein tyrosine phosphatase inhibitors
MXPA05010937A (es) Derivados de fenilalanina n-(1,3-tiazol-2-il)amino)carbonil)fenil)sulfonil) y compuestos relacionados para el tratamiento de diabetes.
WO2006055708A3 (en) Heterocycle substituted carboxylic acids for the treatment of diabetes
TW200630327A (en) Substituted phenylalkanoic acids
MXPA05011524A (es) Acidos carboxilicos sustituidos.
WO2008033455A3 (en) Biphenyl and heteroaryl phenyl derivatives as protein tyrosine phosphatases inhibitors
WO2007127474A3 (en) Compositions and treatments using pyridazine compounds and cholinesterase inhibitors
WO2008074997A8 (en) Pyridine benzamides and pyrazine benzamides used as pkd inhibitors
WO2008033932A3 (en) Biarylthiazole carboxylic acid derivatives as protein tyrosine phosphatase-ib inhibitors
ZA200703002B (en) Preparation and use of biphenyl-4-yl-carbonylamino acid derivatives for the treatment of obesity
WO2006113864A3 (en) Oxindole compounds and their uses as therapeutic agents
MX2009003305A (es) Inhibidores de co-transportador de glucosa de sodio 2 y metodo para su uso.
WO2008002621A3 (en) Benzyl-substituted quinolone m1 receptor positive allosteric modulators
WO2007089857A3 (en) Substituted imidazole derivatives and their use as ptpase inhibitors
HK1124863A1 (en) Inhibitors of sodium glucose co-transporter 2 and methods of their use
HK1079526A1 (en) A novel pyrazine compound and its use in the manufacture of a medicament for treating diseases related to serotonin
MY141528A (en) Anilinopyrazole derivatives useful for the treatment of diabetes
TW200631949A (en) Substituted carboxylic acids
EP1812007A4 (en) PYRIDAZINE COMPOUNDS AND METHODS
EA200501865A1 (ru) Аналоги тиовольфраматов и их применение